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Boosting chemokine receptor recycling: an elixir of life for 
chronic lymphocytic leukemia
Laura Patrussi and Cosima T. Baldari
The stromal microenvironment of lymphoid organs 
is emerging as a key player in regulating both survival 
and chemoresistance of chronic lymphocytic leukemia 
(CLL) cells [1]. Abnormally elevated surface levels of the 
homing receptors CCR7 and CXCR4 [2], and defective 
expression of the egress receptor S1PR1 [3], alter the 
balance between entry to and exit from lymphoid organs, 
prolonging leukemic cell residency in this pro-survival 
niche. 
In addition to transcriptional modulation, the surface 
amount of chemokine receptors is regulated by endosome 
recycling, which allows for rapid re-use of engaged 
receptors without need of new synthesis. Enhanced 
transcription and potentiated recycling cooperate to alter 
the chemokine receptor landscape in CLL cells, eventually 
impacting on leukemic cell residency in the protective 
lymphoid niche. Interestingly, while CCR7 exploits both 
transcription and recycling to upregulate its surface levels 
in CLL cells [2, 3], CXCR4 completely relies on enhanced 
recycling [2]. This finding underlies the importance of 
this mechanism and the serious effects of its imbalance 
in pathological contexts related to altered cell migration. 
We have reported that a defect in the expression 
of the pro-apoptotic adaptor p66Shc in CLL cells [4] 
contributes to CLL pathogenesis by enhancing CCR7 
transcription while concomitantly decreasing S1PR1 
expression [2], thereby promoting leukemic cell 
accumulation in the stromal environment. In our recent 
report [5], based on the ability of p66Shc to negatively 
modulate chemokine receptor signaling [6], we asked 
whether the p66Shc defect is also involved in enhanced 
recycling of CXCR4 and CCR7 in CLL cells. Consistent 
with this hypothesis, results obtained using the CLL-
derived cell line MEC which does not express p66Shc 
[3] transfected with a p66Shc-encoding vector, or B cells 
isolated from p66Shc-/- and wild-type mice, demonstrated 
a negative impact of p66Shc on CXCR4 and CCR7 
recycling. Additionally, the abnormalities in CXCR4 and 
CCR7 recycling in CLL cells could be rescued by forced 
p66Shc expression. Hence the p66Shc defect of CLL 
cells translates into their enhanced ability to recycle these 
receptors.
To dissect the molecular circuitry that connects 
p66Shc to chemokine receptor recycling we tracked 
CXCR4 and CCR7 undergoing recycling in leukemic 
B cells. We found that both become phosphorylated, 
recruit β-arrestin and become internalized in Rab5+ early 
endosomes, a sorting compartment wherefrom internalized 
receptors are directed either to recycling endosomes 
to return to the plasma membrane or to late endosomes 
for their subsequent lysosome-mediated degradation. 
Interestingly, we observed a change in the intracellular 
distribution of CXCR4 and CCR7 in CLL cells, with a 
preferential accumulation in Rab11+ recycling endosomes. 
This was paralleled by an expansion of the surface pool 
of either receptor at the expense of the intracellular pool. 
Interestingly, forced p66Shc expression in these cells 
reverted these abnormalities, indicating that p66Shc 
affects the subcellular distribution of CXCR4 and CCR7 
by slowing down their transit to the endosomal recycling 
compartment, ultimately restraining the surface pool of 
these receptors (Figure 1). 
Having verified that that receptor internalization 
was not affected by p66Shc, we focused on the process 
of receptor dephosphorylation, that allows for β-arrestin 
release and receptor access to the recycling route. 
Immunoprecipitation experiments and flow cytometric 
analyses of the phosphorylated receptors in the MEC 
transfectants as well as in CLL cells showed that both 
receptors were readily dephosphorylated in cells lacking 
p66Shc, consistent with their rapid re-exposure at the 
plasma membrane, while their phosphorylation was 
significantly delayed in p66Shc-overexpressing cells. 
Using pharmacological inhibitors and siRNA-mediated 
knock-down were able to identify PP2B, broadly known 
              Editorial
Figure 1: Enhanced CXCR4 and CCR7 recycling in 
CLL B cells. Schematic representation of enhanced recycling 
of CXCR4 and CCR7 homing receptors in normal B cells 
(HEALTHY) and in leukemic cells from CLL patients (CLL). 
EE: early endosomes; RE: recycling endosomes; P: serine/
threonine phosphorylation.
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as Calcineurin, as the phosphatase responsible for 
dephosphorylating CXCR4 and CCR7. The activity of 
PP2B crucially relies on [Ca2+]i. The ability of p66Shc to 
attenuate [Ca2+]i mobilization in response to CXCR4 and 
CCR7 engagement provides mechanistic insights into the 
inverse correlation between p66Shc expression and PP2B 
activity as well as receptor recycling. 
We were intrigued by the fact that the Btk inhibitor 
ibrutinib, used for the treatment of CLL, potently 
mobilizes leukemic cells from lymph nodes [7]. Our 
previous results provided evidence that ibrutinib promotes 
leukemic cell exit from the stromal niche by normalizing 
the balance between CCR7 and S1PR1 [2]. We now add a 
tile to the puzzle by demonstrating that ibrutinib operates 
by enhancing p66Shc expression in CLL cells, which 
importantly translates into the intracellular accumulation 
of CXCR4/CCR7 as a consequence of their inability to 
transit along the recycling route. Reconstitution of p66Shc 
expression in CLL B cells appears therefore of interest for 
the treatment of this as yet incurable disease. Although 
ibrutinib is already used for CLL treatment, its specific 
molecular target is Btk, confining the p66Shc-elevating 
ability to a side-effect. The development of drugs able to 
specifically enhance p66Shc expression, e.g. by activating 
the p66Shc transcription factor STAT4 [8], might be a 
potential new frontier for the treatment of CLL. 
To our knowledge our report is the only one to date 
to have directly addressed the possibility that alterations 
in the vesicular traffic pathway responsible for chemokine 
receptor recycling might underlie the abnormalities in 
surface expression of CXCR4 and CCR7 and the resulting 
enhancement in leukemic cell homing to the pro-survival 
stromal niche [5]. Dissecting this pathway may unveil 
other molecular players that are modulated in CLL and 
that could be amenable to pharmacological manipulation 
for new personalized therapies.
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